For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery.

This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing.

Topics discussed:

• Tackling GMP manufacturing challenges and analytics development from scratch (00:34)
• Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25)
• Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40)
• Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26)
• Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05)
• Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19)
• Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57)
• Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04)
• The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12)
• Business models for platform out-licensing and potential for co-development partnerships (12:58)
• Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28)

Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources

If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.

• Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
• Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal

Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech

Support the show